CD40 ligand and lipopolysaccharide enhance the in vitro generation of melanoma-reactive T-cells

Journal of Immunological Methods

Volumn 259, Issue 1-2, 2002, Pages 181-190

  Toso, John F ^a   Lapointe, Rejean ^a   Hwu, Patrick ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

CD40 ligand; Lipopolysaccharide; Melanoma reactive T cells

Indexed keywords

CANCER VACCINE; GLYCOPROTEIN GP 100; GLYCOPROTEIN GP 39; LIPOPOLYSACCHARIDE; MELAN A; MONOPHENOL MONOOXYGENASE; TUMOR ANTIGEN;

ANALYTIC METHOD; ANTIGEN PRESENTING CELL; ARTICLE; CELL ACTIVATION; CELL CULTURE; CONTROLLED STUDY; EVALUATION; HUMAN; HUMAN CELL; IMMUNIZATION; LYMPHOCYTOPOIESIS; MELANOMA; MONONUCLEAR CELL; PRIORITY JOURNAL; REPRODUCIBILITY; STEM CELL; T LYMPHOCYTE;

ANTIGEN PRESENTATION; CANCER VACCINES; CD40 LIGAND; CYTOTOXICITY, IMMUNOLOGIC; HUMANS; LIPOPOLYSACCHARIDES; MELANOMA; MONITORING, IMMUNOLOGIC; REPRODUCIBILITY OF RESULTS; T-LYMPHOCYTES, CYTOTOXIC; TUMOR CELLS, CULTURED;

EID: 0036133099     PISSN: 00221759     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-1759(01)00513-0     Document Type: Article

References (24)

1. An expanded peripheral T cell population to a cytotoxic T lymphocyte (CTL)-defined, melanoma-specific antigen in metastatic melanoma patients impacts on the generation of peptide-specific CTLs but does not overcome tumor escape from immune surveillance in metastatic lesions
2. Estimation of the frequencies of anti-MAGE-3 cytolytic T-lymphocyte precursors in blood from individuals without cancer
3. Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A
4. Production of natural killer cell stimulatory factor (interleukin 12) by peripheral blood mononuclear cells
5. Presentation of peptides by cultured monocytes or activated T cells allows specific priming of human cytotoxic T lymphocytes in vitro
6. The toll-receptor family and control of innate immunity
7. Human dendritic cells require multiple activation signals for the efficient generation of tumor antigen-specific T lymphocytes
8. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients
9. Increased vaccine-specific T cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression
10. New trends in the development of cancer vaccines
11. Linking innate and adaptive immunity
12. High frequencies of naïve Melan-A/MART-1-specific CD8+ T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals
13. Ex vivo IFN-gamma secretion by circulating CD8 T lymphocytes: Implications of a novel approach for T cell monitoring in infectious and malignant diseases
14. Dendritic cells at the end of the millennium
15. Coordinated events during bacteria-induced DC maturation
16. Cancer vaccines based on the identification of genes encoding cancer regression antigens
17. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma
18. Recognition of multiple epitopes in the human melanoma antigen gp100 by peripheral blood lymphocytes stimulated in vitro with synthetic peptides
19. Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues
20. Analysis of the cytolytic T lymphocyte response of melanoma patients to the naturally HLA-A*0201-associated tyrosinase peptide 368-376
21. CD40-CD40 ligand
22. The telomerase catalytic subunit is a widely expressed tumor-associate antigen recognized by cytotoxic T lymphocytes
23. Prospects for adoptive T cell therapy
24. Isolation of high avidity melanoma-reactive CTL from heterogeneous population using peptide-MHC tetramers